'Transformative Event' For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi
Portfolio Pulse from Vandana Singh
First Wave BioPharma Inc (FWBI) has entered into a licensing agreement with Sanofi SA (SNY) for Capeserod, a drug that First Wave plans to repurpose for gastrointestinal indications. This follows disappointing results from First Wave's Phase 2 SPAN trial. The agreement includes a modest upfront payment, backend milestone payments, and single-digit royalties on net sales. First Wave will request a meeting with the FDA to establish a development and regulatory pathway for Capeserod.
September 14, 2023 | 10:00 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
First Wave BioPharma's licensing agreement with Sanofi for Capeserod could potentially transform the company's GI-focused development pipeline. However, the company's stock is down following disappointing Phase 2 SPAN trial results.
The licensing agreement with Sanofi could potentially transform First Wave's GI-focused pipeline, which is a positive development. However, the disappointing results from the Phase 2 SPAN trial have negatively impacted the company's stock, leading to a neutral short-term impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Sanofi has entered into a licensing agreement with First Wave BioPharma for Capeserod. The agreement includes a modest upfront payment, backend milestone payments, and single-digit royalties on net sales.
The licensing agreement with First Wave BioPharma for Capeserod could potentially bring in additional revenue for Sanofi through upfront payment, backend milestone payments, and royalties. However, the modest upfront payment and single-digit royalties may not have a significant short-term impact on the company's stock.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 80